World News Insights
1-3 Minute Gist

Browse Articles or use Lyrarc's US patented "Groups" and "Links" for new insights. A Lyrarc Group of Articles on a topic gives insights into particular angles shown in the Group Title. A Lyrarc Link shows more specific insights for 2 articles.

All Topics Articles

LyrArc brings in selected articles from many of the world's top publications.

Articles are selected by experts and you can see the gist of the important articles.


Wall Street Journal Original article ›
Wall Street Journal Original article ›
Wall Street Journal Original article ›
New York Times Original article ›
New York Times Original article ›
Wall Street Journal Original article ›
LyrArc Article Gist
The presidential debate in France for candidates Sarkozy and Hollande between the first round and the runoff elections.
Wall Street Journal Original article ›
LyrArc Article Gist
France plays an important role in helping the newly elected president in Ivory Coast assume office, after an effort to remain in office by his predecessor. Efforts under U.N. auspices to end a conflict in Ivory Coast. This led to close to a million refugees fleeing fighting.
New York Times Original article ›
Wall Street Journal Original article ›
Wall Street Journal Original article ›
LyrArc Article Gist
The shrinking of the 25 point lead of Joko Widodo over a Suharto era general, Subianto, as television networks shift support to Subianto. Indonesia's presidential elections are set for July 9, 2014. Widodo, is a popular governor of Jakarta, and the candidate of the Indonesian Democratic Party of Struggle. Its chairwoman is former president Megawati Sukarnoputri. The slow progress on infrastructure projects in Jakarta, including a light rail line, is affecting Widodo's lead.
Wall Street Journal Original article ›
BusinessWeek Original article ›
LyrArc Article Gist
Novartis is taking a new approach to drug research and drug discovery. The old one which was popular in the drug industry was to go directly for blockbuster drugs for large numbers of users, with a long time in the research pipeline because the area of research was largely an unknown. This was costly and becoming less and less productive. Dan Vasella who heads Novartis, is taking a different approach which comes from his understanding of medical science as a physician, in an industry run by accountants, lawyers and business people. This is to go after wellknown molecular pathways identified by Dr Fishman at Harvard in his research, and do this by taking on problems in diseases that afflict small numbers of people. These drugs have some established medical science to work with, and the research work takes a shorter period. Once the drug proves its effectiveness in one illness, it is tested for other illnesses that afflict a large number of people but which shares some of the same underlying phenomena that cause the disease in the two situations. Dr Vasella stumbled on this approach after the development of the drug Gleevec by Novartis. Gleevec was originally approved for a rare blood cancer, but has now shown to be effective against six other dieases. Gleevec brought 3.7 billion in revenues in 2008 for Novartis. In 2002 Vasella made a bold move to discard the old drug development model. The basis of this approach was to go after new drugs that were desperately needed and where the genetics of the illness were well understood. Whereas pursuing rare dieases is considered foolhardy by most drug company leaders, Vasella's idea is to use the common genetic underlying arrangements for that drug to go after other diseases that would be good prospects for the now proven drug. The known genetics makes it possible to complete the research in a shorter time. In 2009 Novartis has 93 drug candidates in the pipeline, 40% more than 3 years ago and 80% of Novartis' drugs last year made it from early testing to late stage development. This was a 60% improvement over 2005. The new approach fits the current regulatory climate, with regulators concerned more about safety, and Medicare and Medicaid and other payor less willing to pay for treatment with modest benefits or with uncertain outcomes. The approach had to be executed in terms of organization and staffing. Vasella moved the R&D global research operation from Basel to Cambridge, Massachusetts, and spent $4 billion on the move. He recruited a renowed researcher and cardiologist at Harvard University, Dr Mark Fishman, who had done research on the genetic mutations in the cardiovascular systems, to run the center and set the new direction for global research. Fishman convinced Vasella that medical research should focus on a small number of molecular pathways- the complex suquences of interactions among chemicals, proteins, and larger cell structures in the body that are behind all illnesses. Says Fishman, there are 24,000 genes in the genome, but only a few dozen pathways conserved through evolution. Fishman's theory is that you find all the links in a pathway and then locate the signals that can turn the genes on or off to develop medicines for illnesses. Bercause disease after disease share a common pathway, the knowledge gathered can then be applied across that region with more accuracy and directly, to address a range of illnesses. Fishman's approach means marketing and sales no longer make the decisions. There is a new method for doing things. Fishman focusses on clinical data and insists that commercial analysis comes after sufficient clinical data. A major restructuring in 2007 led to shedding 1260 sales and marketing jobs, as clinical science now takes precedence and medically trained scientists take senior leadership positions. The new approach is being used for a drug developed for Muckle-Wells syndrome. Computer simulations are shortening the time to late stage trials. The drug has applications for Type 2 diabetes and severe arthritis. The whole process will take many years, as its a sea change for the industry and for Novartis, a fresh approach when the approach used by the pharmaceutical industry for so long is failing. An oral drug treatment for multiple sclerosis is being developed along these lines. Afinitor. approved by the FDA for kidney cancer in March shows potential in six other diseases, including lymphoma where Afintor shrank tumors by 50% in one third of the patients in a trial. ...
Wall Street Journal Original article ›
New York Times Original article ›
New York Times Original article ›
New York Times Original article ›
Wall Street Journal Original article ›
Wall Street Journal Original article ›
New York Times Original article ›
New York Times Original article ›
LyrArc Article Gist
In 2007 the Pakistan Supreme Court issued rulings that led to the ouster of the army led government of President Musharraf. A similiar situation is occurring today as the Supreme Court issues anti-corruption rulings against the government of President Zardari. The chief justice of the Supreme Court Justice Chaudhry says he is "buttressing democratic and parliamentary norms," as extensive corruption is affecting justice in Pakistan. Critics say Justice Chaudhry was not elected and is now questioning the authority of an elected government.
New York Times Original article ›
Wall Street Journal Original article ›
Washington Post Original article ›
LyrArc Article Gist
Michael Bennet in Colorado, Paul Hodes in New Hampshire, both Democratic candidates, are campaigning for austerity cuts to reduce the deficit. Paul Hodes suggested $3 billion in spending cuts that would remove airport, railroad and housing funds. As Democrats shift to deficit reduction and reducing spending, to keep up with shifting public sentiment; Republican candidates are shifting to radical solutions to reduce the deficit, including shutting down some federal agencies. This may result in an entirely different Congress ater the midterm elections- one focussed on deficit reduction just as the economy slows down as stimulus fades, and local governments cut back.
Wall Street Journal Original article ›
New York Times Original article ›

Support LyrArc

We took a different way to help millions around the world build educated informed mindsets that affects and shapes their lives. For a future that is open, global and digital, with everyone having access to high quality information. We believe in the renewal of America, renewal of Europe, the renewal of India, the rest of Asia, Latin America and Africa. The renewal of our supply chains, health, education, infrastructure, as we rebuild our countries after the pandemic. Literacy and knowledge we believe cannot thrive and grow in a world of web bots, web crawlers, or AI. This requires human curiosity, human learning, and human imagination. We take as inspiration the saying- “One has to be free, and as broad as sky. One has to have a mind that is crystal clear, only then can truth shine in it.” Every contribution whether big or small is precious- in this crisis and ahead.

Support Lyrarc from as small as $1


Copyright © 2006 - 2026 Intelilinks LLC
Terms and Conditions | Copyright Policy | Privacy Policy | Contact Us